Lamivudine Adjusted

Lamivudine Adjusted: Dose modification based on renal function to prevent drug accumulation and toxicity.

mg/dLumol/L
mg/dLumol/L
ml/minml/24hrL/24hr

Indications for Use

Used for chronic hepatitis B when no better high–barrier NA is available and for HBV/HIV coinfection as part of combination ART (never as HBV monotherapy due to high resistance per EASL 2025 1). Provides HBV DNA suppression and reduces MTCT risk in pregnancy when alternatives are unavailable (Lancet ID RCT/meta-analysis OR≈0.16 for MTCT 2). Considered adjunctive in HIV ART for dual HBV/HIV activity.

Insights & Cautions

Use dose‑reduce in renal impairment: CrCl 30–49 → 100 mg first dose then 50 mg daily; 15–29 → 100 mg then 25 mg daily; 5–14 → 35 mg then 15 mg daily; <5 → 35 mg then 10 mg daily 1 [Level I evidence]. Monitor for lactic acidosis and pancreatitis 2 [Level III evidence]. Long‑term use carries high resistance risk (65% by year 5) 3 [Level II evidence]. Pregnancy generally safe. No hepatic dose adjustment needed.